GILD

Gilead Sciences
D

GILD

Arincen87/100B
166.870
USD
-0.73
(-0.44%)
Pre Open·168.040USD+1.170(+0.70%)
Last updated: · Delayed 15 min

Gilead Sciences debt to equity ratio

Gilead Sciences's debt to equity ratio is 2.01: total debt of 26.23B USD against shareholders' equity of 13.04B USD.

Today
2.01
Average, 5 years
1.31
Low, 5 years
0.94
High, 5 years
2.22

Debt to equity = total debt ÷ shareholders' equity = 26.23B ÷ 13.04B = 2.01

Debt to equity
Total debt
Shareholders' equity

Total debt over shareholders' equity at each quarter end.

Debt to equity by year and by quarter

Fiscal yearPeriod endingDebt to equityTotal debtShareholders' equity
Today2.0126.23B13.04B
FY202531 Dec 20251.1024.94B22.70B
FY202431 Dec 20241.3826.71B19.33B
FY202331 Dec 20231.0924.99B22.83B
FY202231 Dec 20221.1925.23B21.24B
FY202131 Dec 20211.2726.70B21.07B
FY202031 Dec 20201.7331.40B18.20B
FY201931 Dec 20191.0924.59B22.53B
FY201831 Dec 20181.2827.32B21.39B
FY201731 Dec 20171.6433.54B20.44B
FY201631 Dec 20161.3926.35B18.89B
FY201531 Dec 20151.1922.06B18.53B
FY201431 Dec 20140.8012.40B15.43B
FY201331 Dec 20130.586.64B11.37B
FY201231 Dec 20120.888.22B9.30B
FY201131 Dec 20111.137.61B6.74B
FY201031 Dec 20100.593.48B5.86B
FY200931 Dec 20090.201.25B6.37B
FY200831 Dec 20080.271.16B4.27B
FY200731 Dec 20070.381.31B3.46B
FY200631 Dec 20060.781.41B1.82B
FY200531 Dec 20050.10300.86M3.03B
FY200431 Dec 20040.00415.00K1.87B
FY200331 Dec 20030.34345.46M1.00B
FY200231 Dec 20021.04595.47M571.34M
FY200131 Dec 20010.56251.88M452.44M
FY200031 Dec 20000.73255.27M351.12M
FY199931 Dec 19990.3087.98M297.29M
FY199831 Dec 19980.30101.50M333.70M
FY199731 Dec 19970.013.20M317.30M
FY199631 Dec 19960.026.50M291.70M
FY199531 Dec 19950.046.40M151.50M
FY199431 Dec 19940.108.40M86.10M
FY199231 Dec 19920.011.80M139.40M
FY199131 Dec 19910.011.00M105.60M
FY199031 Dec 19900.08800.00K10.20M

Figures in USD. A quarter's revenue, net income and dividends are those of its last four quarters.

See also:P/E ratio,Market cap,P/S ratio,Dividend yield,ROE (return on equity),Current ratio,All ratios

Common questions about Gilead Sciences's debt to equity

Source: Financial Modeling Prep

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.